AngioSense And Repair Agree Cardiovascular Collaboration

AngioSense Inc., and Boston-based Repair Inc. are to jointly pursue clinical applications for sustained delivery of fibroblast growth factor (FGF) to stimulate the growth of new blood vessels in diseased hearts.

Under the agreement, AngioSense will supply its needle-free, jet injection delivery systems and Repair will provide proprietary FGF protein and fibrinogen constructs.

Financial details were not disclosed.

The collaboration stems from positive results from pre-clinical studies using the AngioSense needle-free, jet injection delivery system with Repair’s FGF formulation.

“We are very eager to combine our growth-factor technology with AngioSense’s needle-free drug delivery system,” said Spiros Jamas, Sc.D., president and CEO of Repair Inc. “Angiogenic proteins such as fibroblast growth factor potentially offer a powerful biological approach to treating coronary artery disease by stimulating the growth of new blood vessels, and a safe and efficient drug delivery system will be critical to the success of this therapeutic approach.”

David Opie, Ph.D., president and CEO of AngioSense, said, “Using our needle-free, jet injection drug delivery methods, our collaborators expect to benefit from local, sustained drug delivery of FGF to stimulate the formation of functional new blood vessels, resulting in improved blood flow and heart function. Our partnership promises to be the best combination of two state-of-the-art technologies to advance the development of this novel approach.”

Repair Inc., based in Boston, is applying proprietary drug delivery technologies and angiogenic agents to develop a pipeline of biological therapeutics to treat cardiovascular disease.

The company is initially developing products to treat CAD, PVD and other cardiovascular diseases.

AngioSense Inc. is focused on developing innovative, safe and efficient surgical and cardiology-based devices for needle-free, jet- injection local drug delivery applications.

Founded in 1999, the privately held company is developing catheter-based and minimally invasive surgical devices for targeted delivery of gene therapy solutions.

Its unique systems-design platform enables the clinician to reach sites that are inaccessible to conventional syringe-based injection methods currently employed.

AngioSense‘s products can be developed for application in any procedural setting and in conjunction with other technologies.

Legal Steroids

Dragon Pharma has provided our clients the highest level of pharmacy services throughout the continuum of the overall healthcare system: Trenbolone 200.